Aspira Women's Health Files 8-K on Shareholder Vote and Financials

TL;DR

Aspira Women's Health filed an 8-K on May 13th for shareholder votes and financials.

AI Summary

Aspira Women's Health Inc. filed an 8-K on May 14, 2024, reporting on a submission of matters to a vote of security holders and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal business address in Austin, Texas. It also lists former company names, indicating a history of mergers and name changes.

Why It Matters

This filing provides an update on corporate governance and financial reporting for Aspira Women's Health Inc., which is relevant for investors tracking the company's operational and shareholder-related activities.

Risk Assessment

Risk Level: low — This is a routine 8-K filing related to corporate governance and financial reporting, not indicating any immediate operational or financial distress.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• May 13, 2024 (date) — Earliest event reported
• May 14, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Austin, Texas (location) — Business address
• VERMILLION, INC. (company) — Former company name
• CIPHERGEN BIOSYSTEMS INC (company) — Former company name
• ABIOTIC SYSTEMS (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market

Filing Documents

• awh-20240513.htm (8-K) — 91KB
• 0000950170-24-059543.txt ( ) — 215KB
• awh-20240513.xsd (EX-101.SCH) — 31KB
• awh-20240513_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 13, 2024, Aspira Women's Health Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). As of the close of business on the record date for the Annual Meeting, there were 12,344,104 shares of the Company's common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 8,093,336 shares present in person or by proxy at the Annual Meeting, constituting a quorum. The final voting results were as follows: Proposal 1: Election of Directors The Company's stockholders elected each of the Company's six nominees for director for a one-year term expiring at the Company's 2025 annual meeting of stockholders and until their successors are elected and qualified, as set forth below: NOMINEE FOR AGAINST ABSTENTIONS BROKER NON-VOTES Stefanie Cavanaugh 4,213,732 69,683 5,564 3,804,357 Celeste R. Fralick, Ph.D. 4,220,435 67,647 897 3,804,357 Jannie Herchuk 4,210,555 72,860 5,564 3,804,357 Lynn O'Connor Vos 4,215,103 72,978 898 3,804,357 Nicole Sandford 4,183,242 93,278 12,459 3,804,357 Winfred Parnell, M.D. 4,214,222 73,859 898 3,804,357 Proposal 2: Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,189,574 97,653 1,752 3,804,357 Proposal 3: Approval of an Amendment to the Aspira Women's Health Inc. 2019 Stock Incentive Plan The Company's stockholders approved an amendment to the Company's 2019 Stock Incentive Plan (the "2019 Plan") to increase the number of shares of common stock authorized to be granted under the 201

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: May 14, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR